NORCROSS, Ga., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that it has entered into a $20 million convertible debt financing agreement with Richard E.
NORCROSS, Ga., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the Company’s management will present at the H.C. Wainwright 23rd Annual Global Investment Conference.
NORCROSS, Ga., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company has recently expanded its management team with multiple key leadership appointments, including Dakshina
Considering options for a Combination Cancer Immunotherapy trial based on encouraging results of Phase 1b trial which strengthened the rationale to conduct a larger, randomized controlled Phase 2 study NORCROSS, Ga., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.
Belapectin and KEYTRUDA ® combination immunotherapy in patients with treatment-refractory and progressive diseases shows a cancer control rate of 56% in melanoma and of 40% in head and neck cancer Melanoma patients in the study had a particularly severe prognosis, with four out of nine having
Continued Favorable Developments in both NAVIGATE and Cancer Combination Immunotherapy Trials NORCROSS, Ga., May 17, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided
NORCROSS, Ga., April 27, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Pol F. Boudes, M.D., Chief Medical Officer , will present the belapectin program at the 4th Global NASH Congress
Galectin Therapeutics also announces new $10 million convertible debt financing from its Chairman, Richard E. Uihlein NORCROSS, Ga., April 19, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced it
Combination therapy with belapectin suggests a better objective response rate with fewer adverse events than pembrolizumab (KEYTRUDA®) alone NORCROSS, Ga., April 13, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin
Galectin Therapeutics is actively recruiting patients into NAVIGATE, its seamless, adaptive Phase 2b/3 study of belapectin for the prevention of esophageal varices in NASH cirrhosis NORCROSS, Ga., April 06, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.
